Tab Application Banner
  • Users Online: 621
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
 
ORIGINAL ARTICLE
Ahead of Print

Utility of anti-carbamylated protein antibodies in the diagnosis of early rheumatoid arthritis


1 Rheumatology and Immunology Unit, Department of Internal Medicine, Faculty of Medicine, Mansoura University, Mansoura, Egypt
2 Rheumatology and Rehabilitation Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
3 Rheumatology and Rehabilitation Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt
4 Clinical Pathology Department, Faculty of medicine, Mansoura University, Mansoura, Egypt
5 Clinical Pathology Department, Faculty of medicine, Al-Azhar University, Cairo, Egypt

Correspondence Address:
Ashraf H Mohamed,
Department of Internal Medicine, Faculty of Medicine, Mansoura University, Elgomhoria Street, Mansoura
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/injr.injr_110_18

Background: Anti-carbamylated protein (anti-CarP) antibodies are present in patients with Rheumatoid arthritis (RA) and may present before disease onset. Our aim is to investigate the diagnostic value of anti-CarP antibody in Egyptian RA patients. Methods: This cross-sectional study included 96 RA patients (56 patients with early disease and 40 patients with established disease) and 60 healthy controls. Demographic and clinical data, smoking status, and disease activity score were recorded. Laboratory tests included erythrocyte sedimentation rate, C-reactive protein, rheumatoid factor, anti-citrullinated protein antibodies, and anti-CarP antibody. Results: Anti-CarP antibody levels in RA patients were significantly higher than in controls (8.80 ± 5.95 vs. 2.19 ± 1.01, P < 0.0001). Out of 96 RA patients; 74 (77.1%) were positive for anti -CarP anti body including 47patients with early RA while only 5 subjects (8.3%) in control group were positive. Receiver-operating characteristic curve study for diagnostic efficacy of anti-CarP antibody in early RA diagnosis demonstrated a significant area under the curve, 0.950 (95% confidence interval, 0.912–0.987, P < 0.0001) and yielded a sensitivity of 85.4%, a specificity of 93.3%, a positive predictive value of 0.90, and a negative predictive value of 0.86. Conclusion: Anti-CarP antibody is a useful biomarker for early RA diagnosis.


Print this article
Search
 Back
 
  Search Pubmed for
 
    -  Mohamed AH
    -  Enein A
    -  Abdelsalam N
    -  Balata M
    -  Abdellatif S
    -  Rizk E
    -  Fathy A
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed188    
    PDF Downloaded17    

Recommend this journal